BiotechTube
Home/Pipeline/CDX-527

CDX-527

Oncology (Solid Tumors)

Phase 1Active

Key Facts

Indication
Oncology (Solid Tumors)
Phase
Phase 1
Status
Active
Company
Celldex Therapeutics

About Celldex Therapeutics

Celldex Therapeutics is a disciplined, R&D-focused biotech with a 40-year legacy, strategically pivoted to become a leader in developing targeted antibody therapeutics for immunology and oncology. Its most advanced asset, barzolvolimab, a mast cell-depleting KIT inhibitor, has demonstrated compelling late-stage data in chronic urticaria and is advancing in multiple inflammatory indications, positioning the company for near-term commercialization. Celldex's strategy leverages proprietary antibody platforms and in-house capabilities to build a diversified pipeline aimed at addressing root causes of disease beyond symptomatic management.

View full company profile

Therapeutic Areas

Inflammatory DiseasesOncologyAllergic DiseasesAutoimmune Disorders

Other Oncology (Solid Tumors) Drugs

DrugCompanyPhase
OATD-02MolecurePhase I
Athebody® DARPins for Targeted Radioligands (with POINT Biopharma)AthebioPre-clinical
AB821Asher BiotherapeuticsPreclinical
Undisclosed Preclinical PipelineOncoResponsePreclinical
Undisclosed Platform ProgramDa Zen TheranosticsPre-clinical
Compound42Abbmira TherapeuticsPre-clinical
Clinical Decision Support ServiceCurematchCommercial
CV6-168CV6 TherapeuticsPhase 1a
Chemophototherapy (CPT)POP BiotechnologiesPre-clinical
HRD Testing SolutionSeqOne GenomicsCommercial
Platform Validation & Partnership DevelopmentSingleCell BiotechnologyPre-clinical
UndisclosedY-TrapPreclinical